Developer docs
API playgroundTry for free, no card

Search company profiles

Sudo Biosciences

Full company profile

uuid0000kum

Namestring
Sudo Biosciences
Legal namestring
Sudo Biosciences, Inc.
Websiteurl
sudobio.com
Company typeenum
Private
Founded yearint
2020
Descriptiontext

Sudo Biosciences is a clinical-stage biopharmaceutical company founded in 2020 and headquartered in Carmel, Indiana, with additional operations in London, United Kingdom. The company designs and develops small-molecule medicines that selectively inhibit tyrosine kinase 2 (TYK2) through its regulatory pseudokinase (JH2) domain, an allosteric approach intended to deliver potent pathway blockade with minimized off-target activity compared to traditional JAK family inhibitors that target the catalytic JH1 domain. Its pipeline currently comprises three programs: SUDO-550, an oral, brain-penetrant allosteric TYK2 inhibitor for multiple sclerosis and other neuroinflammatory and neurodegenerative conditions (Phase 1 completed with a Phase 2 MS study planned for H1 2026); SUDO-286, a topical TYK2 inhibitor for psoriasis and immune-mediated dermatologic diseases (Phase 1); and a preclinical ophthalmic TYK2 program. The company is led by a management team with prior operating experience at Pfizer, Eli Lilly, Array Biopharma, GW Pharmaceuticals, Mitsubishi Tanabe, and Frazier Life Sciences.

The company's underlying technology platform centers on medicinal chemistry optimization of allosteric TYK2 JH2 binders, combined with translational biology capabilities that integrate human genetic evidence, proteomics, and disease-relevant biomarkers to support target selection and clinical development. Phase 1 results for SUDO-550 demonstrated >90% inhibition of TYK2-mediated signaling with equivalent free concentrations in plasma and cerebrospinal fluid, supporting once-daily oral dosing and CNS penetration — a profile that addresses a major limitation of existing MS therapies that do not adequately target the neurodegenerative component of disease. The topical SUDO-286 program is designed to achieve localized TYK2 inhibition in dermatologic indications with the aim of improving the safety profile relative to systemic JAK inhibitors.

Sudo Biosciences is pre-revenue and generates no commercial product sales. The business model is structured around advancing proprietary drug candidates through clinical development to regulatory approval, with future revenue intended to come from the commercialization of FDA-approved TYK2 inhibitor therapies via prescription drug distribution channels (specialty pharmacies, hospital systems, retail pharmacies). To date the company has financed operations through equity capital, raising $188 million in cumulative funding across a $37 million Series A (September 2022) and a $147 million Series B (December 2023 initial close plus January 2024 second close), with lead investors including Frazier Life Sciences, Velosity Capital, Enavate Sciences, and TPG.

Short descriptiontext

Sudo Biosciences is a clinical-stage biopharmaceutical company developing allosteric small-molecule TYK2 (tyrosine kinase 2) pseudokinase inhibitors for serious neurological and immunological conditions, including multiple sclerosis, neurodegenerative diseases, and psoriasis. The company is pre-revenue and financed through venture capital.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersCarmel, United States
HQ citystring
Carmel
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices4 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
TYK2 inhibitors, autoimmune therapeutics, multiple sclerosis treatments, allosteric kinase inhibitors, biopharmaceutical drug development
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Biopharmaceuticals
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Pharmaceutical Product Revenue
TypeOne Time License
Description

Pre-revenue clinical stage biopharmaceutical company. Revenue will be generated through the commercialization of FDA-approved TYK2 inhibitor therapies for autoimmune and neurological diseases upon successful completion of clinical trials and regulatory approval.

sudobio.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Sudo Biosciences is a clinical-stage biopharmaceutical company developing next-generation small molecule medicines that inhibit tyrosine kinase 2 (TYK2) through its pseudokinase (JH2) regulatory domain. Its lead candidate SUDO-550 is an oral, brain-penetrant allosteric TYK2 inhibitor for multiple sclerosis and other neurodegenerative diseases; SUDO-286 is a topical TYK2 inhibitor for psoriasis and immune-mediated dermatologic conditions; an ophthalmic TYK2 program is in preclinical development. The company designs and develops these precision TYK2 therapeutics for serious neurological and immunological conditions.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Phase 1 results demonstrated SUDO-550 was safe, well tolerated, and achieved >90% inhibition of TYK2-mediated signaling
+2 more records
Product overview1 text field

Sudo Biosciences is a clinical-stage biopharmaceutical company developing next-generation TYK2 (tyrosine kinase 2) pseudokinase inhibitors. The company's pipeline consists of three distinct product candidates: SUDO-550 (a brain-penetrant oral inhibitor for multiple sclerosis and neurodegenerative diseases, currently in Phase 1), SUDO-286 (a topical inhibitor for dermatological conditions including psoriasis, in Phase 1), and an ophthalmic program (preclinical). The company leverages allosteric inhibition targeting the TYK2 pseudokinase (JH2) domain for selectivity over other JAK family members. Based in Carmel, IN and London, UK, Sudo is advancing these precision medicines for immune-mediated and neurological conditions.

Product and service3 records
1SUDO-550
CategoryTYK2 inhibitor drug candidate (CNS / neuroinflammation)
Description

SUDO-550 is a potential first-in-class and best-in-class, oral, CNS-penetrant allosteric TYK2 (tyrosine kinase 2) pseudokinase inhibitor designed for once-daily dosing. It achieves potent and selective inhibition of TYK2-mediated signaling across both the central nervous system and peripheral immune systems, targeting the IL-12, IL-23, and Type I interferon pathways. It is being developed for multiple sclerosis and other neurodegenerative conditions with underlying neuroinflammation and is currently in Phase 1 with a planned Phase 2 in MS in H1 2026.

2SUDO-286
CategoryTYK2 inhibitor drug candidate (topical / dermatology)
Description

SUDO-286 is a highly potent, selective, and potential first- and best-in-class topical TYK2 pseudokinase inhibitor being developed for psoriasis and other immune-mediated dermatologic diseases. It is being evaluated in two Phase 1 clinical studies in healthy volunteers and patients.

3Ophthalmic TYK2 Inhibitor Program
Scale indicator8 records

Each record includes

Type, Value, Description, Source

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Markets Ocrevus and other MS therapies, setting the standard of care against which SUDO-550's Phase 2 MS readout will be benchmarked. Also relevant as a potential strategic acquirer of differentiated CNS candidates.

TypeEmerging player
Description

Clinical-stage biotech developing targeted protein degradation immunology drugs (e.g., KT-474). Comparable as a well-funded, private/platform-based autoimmune biotech pursuing differentiated mechanisms against validated targets.

TypeBroad incumbent
Description

Licensed Nimbus's allosteric TYK2 program (NDI-034858 / zasocitinib) and is actively developing it in psoriasis and IBD. Direct competing oral TYK2 mechanism with deep CNS and autoimmune commercial reach.

4Dice Therapeutics
TypeEmerging player
Description

Was a private DEL-based oral IL-17/TYK2-adjacent immunology company acquired by Eli Lilly for ~$2.4B in 2023. Highly comparable as an autoimmune-focused platform that reached an exit while still clinical-stage.

TypeBroad incumbent
Description

Markets Rinvoq (upadacitinib) and Skyrizi (risankizumab), major immunology franchises targeting overlapping IL-12/IL-23/JAK pathways. Sets the efficacy and commercial benchmark Sudo's candidates will need to beat in psoriasis and autoimmune indications.

TypeBroad incumbent
Description

Markets Litfulo (ritlecitinib) and Cibinqo (abrocitinib) and historically led TYK2/JAK clinical development. Many Sudo executives (Mills, McMurray, Eccles) came from Pfizer, making it both a talent feeder and a competitive reference point.

TypeEmerging player
Description

Private, computationally driven drug discovery company with a TYK2 allosteric inhibitor program (NDI-034858 / takeverant) licensed to Takeda for autoimmune disease. Direct mechanistic parallel to Sudo's platform.

TypeBroad incumbent
Description

Major neuroscience-focused biopharma with the leading MS franchise (Tysabri, Tecfidera, Vumerity). Comparable as a partner or acquirer of differentiated CNS candidates and as the benchmark commercial entity for MS launches.

TypeEmerging player
Description

Clinical-stage immunology company developing allosteric TYK2 inhibitors (e.g., ESK-001) for autoimmune disease, with significant funding from institutional investors. Closely comparable as a private TYK2-focused peer pursuing the same pseudokinase mechanism.

10Bristol Myers Squibb
TypeBroad incumbent
Description

Markets Sotyktu (deucravacitinib), the first FDA-approved allosteric TYK2 inhibitor for psoriasis, and is expanding into additional immunology indications. It is the most important direct competitor to Sudo's oral and topical TYK2 programs.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles17 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors12 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Sudo Biosciences

Biopharmaceuticalssudobio.com

Sudo Biosciences is a clinical-stage biopharmaceutical company developing allosteric small-molecule TYK2 (tyrosine kinase 2) pseudokinase inhibitors for serious neurological and immunological conditions, including multiple sclerosis, neurodegenerative diseases, and psoriasis. The company is pre-revenue and financed through venture capital.

What Sudo Biosciences does

Sudo Biosciences is a clinical-stage biopharmaceutical company founded in 2020 and headquartered in Carmel, Indiana, with additional operations in London, United Kingdom. The company designs and develops small-molecule medicines that selectively inhibit tyrosine kinase 2 (TYK2) through its regulatory pseudokinase (JH2) domain, an allosteric approach intended to deliver potent pathway blockade with minimized off-target activity compared to traditional JAK family inhibitors that target the catalytic JH1 domain. Its pipeline currently comprises three programs: SUDO-550, an oral, brain-penetrant allosteric TYK2 inhibitor for multiple sclerosis and other neuroinflammatory and neurodegenerative conditions (Phase 1 completed with a Phase 2 MS study planned for H1 2026); SUDO-286, a topical TYK2 inhibitor for psoriasis and immune-mediated dermatologic diseases (Phase 1); and a preclinical ophthalmic TYK2 program. The company is led by a management team with prior operating experience at Pfizer, Eli Lilly, Array Biopharma, GW Pharmaceuticals, Mitsubishi Tanabe, and Frazier Life Sciences.

The company's underlying technology platform centers on medicinal chemistry optimization of allosteric TYK2 JH2 binders, combined with translational biology capabilities that integrate human genetic evidence, proteomics, and disease-relevant biomarkers to support target selection and clinical development. Phase 1 results for SUDO-550 demonstrated >90% inhibition of TYK2-mediated signaling with equivalent free concentrations in plasma and cerebrospinal fluid, supporting once-daily oral dosing and CNS penetration — a profile that addresses a major limitation of existing MS therapies that do not adequately target the neurodegenerative component of disease. The topical SUDO-286 program is designed to achieve localized TYK2 inhibition in dermatologic indications with the aim of improving the safety profile relative to systemic JAK inhibitors.

Sudo Biosciences is pre-revenue and generates no commercial product sales. The business model is structured around advancing proprietary drug candidates through clinical development to regulatory approval, with future revenue intended to come from the commercialization of FDA-approved TYK2 inhibitor therapies via prescription drug distribution channels (specialty pharmacies, hospital systems, retail pharmacies). To date the company has financed operations through equity capital, raising $188 million in cumulative funding across a $37 million Series A (September 2022) and a $147 million Series B (December 2023 initial close plus January 2024 second close), with lead investors including Frazier Life Sciences, Velosity Capital, Enavate Sciences, and TPG.

Sudo Biosciences firmographics

Firmographics
Name
Sudo Biosciences
Legal name
Sudo Biosciences, Inc.
Website
https://sudobio.com
Company type
Private
Founded year
2020
Operating status
Operating
Headcount range
11–50 employees
Short description
Sudo Biosciences is a clinical-stage biopharmaceutical company developing allosteric small-molecule TYK2 (tyrosine kinase 2) pseudokinase inhibitors for serious neurological and immunological conditions, including multiple sclerosis, neurodegenerative diseases, and psoriasis. The company is pre-revenue and financed through venture capital.
Ownership category
akta.pro rank

Where Sudo Biosciences is headquartered

Location

Headquarters

HQ city
Carmel
HQ country
United States
HQ region
North America

Offices4 records

Markets served

Sudo Biosciences business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales

Revenue model

  1. Pharmaceutical Product Revenue: Pre-revenue clinical stage biopharmaceutical company. Revenue will be generated through the commercialization of FDA-approved TYK2 inhibitor therapies for autoimmune and neurological diseases upon successful completion of clinical trials and regulatory approval.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Sudo Biosciences product offering

Product offering

Core offering

Sudo Biosciences is a clinical-stage biopharmaceutical company developing next-generation small molecule medicines that inhibit tyrosine kinase 2 (TYK2) through its pseudokinase (JH2) regulatory domain. Its lead candidate SUDO-550 is an oral, brain-penetrant allosteric TYK2 inhibitor for multiple sclerosis and other neurodegenerative diseases; SUDO-286 is a topical TYK2 inhibitor for psoriasis and immune-mediated dermatologic conditions; an ophthalmic TYK2 program is in preclinical development. The company designs and develops these precision TYK2 therapeutics for serious neurological and immunological conditions.

Product overview

Sudo Biosciences is a clinical-stage biopharmaceutical company developing next-generation TYK2 (tyrosine kinase 2) pseudokinase inhibitors. The company's pipeline consists of three distinct product candidates: SUDO-550 (a brain-penetrant oral inhibitor for multiple sclerosis and neurodegenerative diseases, currently in Phase 1), SUDO-286 (a topical inhibitor for dermatological conditions including psoriasis, in Phase 1), and an ophthalmic program (preclinical). The company leverages allosteric inhibition targeting the TYK2 pseudokinase (JH2) domain for selectivity over other JAK family members. Based in Carmel, IN and London, UK, Sudo is advancing these precision medicines for immune-mediated and neurological conditions.

Differentiator

Problem solved

Functional benefit

Products and services

  • SUDO-550 SUDO-550 is a potential first-in-class and best-in-class, oral, CNS-penetrant allosteric TYK2 (tyrosine kinase 2) pseudokinase inhibitor designed for once-daily dosing. It achieves potent and selective inhibition of TYK2-mediated signaling across both the central nervous system and peripheral immune systems, targeting the IL-12, IL-23, and Type I interferon pathways. It is being developed for multiple sclerosis and other neurodegenerative conditions with underlying neuroinflammation and is currently in Phase 1 with a planned Phase 2 in MS in H1 2026.
  • SUDO-286 SUDO-286 is a highly potent, selective, and potential first- and best-in-class topical TYK2 pseudokinase inhibitor being developed for psoriasis and other immune-mediated dermatologic diseases. It is being evaluated in two Phase 1 clinical studies in healthy volunteers and patients.
  • Ophthalmic TYK2 Inhibitor Program

Quantifiable outcome

  • Phase 1 results demonstrated SUDO-550 was safe, well tolerated, and achieved >90% inhibition of TYK2-mediated signaling
  • +2 more outcomes

Companies that use Sudo Biosciences

Customer profile

Segments2 records

Ideal customer profiles3 records

Sudo Biosciences technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Sudo Biosciences partnerships and signals

Strategic signal

Scale indicators8 records

Recent moves6 records

Expansion highlights6 records

Sudo Biosciences competitors and assessment

Company assessment

Broad incumbents

  • Roche: Markets Ocrevus and other MS therapies, setting the standard of care against which SUDO-550's Phase 2 MS readout will be benchmarked. Also relevant as a potential strategic acquirer of differentiated CNS candidates.
  • Takeda Pharmaceutical: Licensed Nimbus's allosteric TYK2 program (NDI-034858 / zasocitinib) and is actively developing it in psoriasis and IBD. Direct competing oral TYK2 mechanism with deep CNS and autoimmune commercial reach.
  • AbbVie: Markets Rinvoq (upadacitinib) and Skyrizi (risankizumab), major immunology franchises targeting overlapping IL-12/IL-23/JAK pathways. Sets the efficacy and commercial benchmark Sudo's candidates will need to beat in psoriasis and autoimmune indications.
  • Pfizer: Markets Litfulo (ritlecitinib) and Cibinqo (abrocitinib) and historically led TYK2/JAK clinical development. Many Sudo executives (Mills, McMurray, Eccles) came from Pfizer, making it both a talent feeder and a competitive reference point.
  • Biogen: Major neuroscience-focused biopharma with the leading MS franchise (Tysabri, Tecfidera, Vumerity). Comparable as a partner or acquirer of differentiated CNS candidates and as the benchmark commercial entity for MS launches.
  • Bristol Myers Squibb: Markets Sotyktu (deucravacitinib), the first FDA-approved allosteric TYK2 inhibitor for psoriasis, and is expanding into additional immunology indications. It is the most important direct competitor to Sudo's oral and topical TYK2 programs.

Emerging players

  • Kymera Therapeutics: Clinical-stage biotech developing targeted protein degradation immunology drugs (e.g., KT-474). Comparable as a well-funded, private/platform-based autoimmune biotech pursuing differentiated mechanisms against validated targets.
  • Dice Therapeutics: Was a private DEL-based oral IL-17/TYK2-adjacent immunology company acquired by Eli Lilly for ~$2.4B in 2023. Highly comparable as an autoimmune-focused platform that reached an exit while still clinical-stage.
  • Nimbus Therapeutics: Private, computationally driven drug discovery company with a TYK2 allosteric inhibitor program (NDI-034858 / takeverant) licensed to Takeda for autoimmune disease. Direct mechanistic parallel to Sudo's platform.
  • Alumis: Clinical-stage immunology company developing allosteric TYK2 inhibitors (e.g., ESK-001) for autoimmune disease, with significant funding from institutional investors. Closely comparable as a private TYK2-focused peer pursuing the same pseudokinase mechanism.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks7 records

Key highlights7 records

Customer concentration

Sudo Biosciences social profiles

Digital presence

Sudo Biosciences financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Sudo Biosciences leadership team

Management profile

Number of profiles

Profiles17 records

Sudo Biosciences funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors12 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Sudo Biosciences M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Sudo Biosciences

What does Sudo Biosciences do?

Sudo Biosciences is a clinical-stage biopharmaceutical company developing next-generation small molecule medicines that inhibit tyrosine kinase 2 (TYK2) through its pseudokinase (JH2) regulatory domain. Its lead candidate SUDO-550 is an oral, brain-penetrant allosteric TYK2 inhibitor for multiple sclerosis and other neurodegenerative diseases; SUDO-286 is a topical TYK2 inhibitor for psoriasis and immune-mediated dermatologic conditions; an ophthalmic TYK2 program is in preclinical development. The company designs and develops these precision TYK2 therapeutics for serious neurological and immunological conditions.

Is Sudo Biosciences a public or private company?

Sudo Biosciences is a private company. It is classified as venture growth investor backed and is currently operating.

When was Sudo Biosciences founded?

Sudo Biosciences was founded in 2020. It employs 11 to 50 people.

Where is Sudo Biosciences based?

Sudo Biosciences is headquartered in Carmel, United States, in the North America region.

How does Sudo Biosciences make money?

One revenue line is on record: pharmaceutical Product Revenue.

Who are Sudo Biosciences's main competitors?

Broad incumbents on record are Roche, Takeda Pharmaceutical, AbbVie, Pfizer, Biogen and Bristol Myers Squibb. Emerging players are Kymera Therapeutics, Dice Therapeutics, Nimbus Therapeutics and Alumis.

Does Sudo Biosciences have an API?

No public API is recorded for Sudo Biosciences.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
The Global Legal PostTrio of US biotech companies appoint legal chiefs amid venture funding recoveryThree US biotechnology companies—Sudo Biosciences, PepGen, and Tonix Pharmaceuticals—have each appointed new legal heads within the past week. The hires follow a strong rebound in biotech venture funding, which rose 70.9% to $3.1 billion in Q3 from $1.8 billion in Q2, after a two-year investment downturn in the sector. Sudo Biosciences is developing TYK2 inhibitors for autoimmune conditions, PepGen focuses on oligonucleotide therapies for neuromuscular and neurological diseases, and Tonix Pharmaceuticals manufactures non-opioid analgesic medicines for fibromyalgia.PharmiWeb.comSudo Biosciences Appoints Paul Bavier as Chief Legal CounselSudo Biosciences, a clinical-stage biopharmaceutical company developing TYK2 inhibitors for immune-mediated diseases, has appointed Paul S. Bavier as Chief Legal Officer. Bavier brings more than two decades of biotech experience, including serving as founding General Counsel at HilleVax through its IPO and prior roles at VelosBio (acquired by Merck) and Avedro (acquired by Glaukos). The company states the appointment will support its global expansion and advancement of its pipeline of next-generation TYK2 inhibitors for multiple sclerosis, neuroinflammatory, and dermatologic conditions.SecSEC FORM DSudo Biosciences, Inc. filed a Form D with the SEC to report an exempt offering of securities under Rule 506(b). The company disclosed a total offering amount of $161,763,255, with $63,596,587 already sold to 15 investors as of the filing date.Pulse 2.0Sudo Biosciences: Second Close Of Upsized Series B Funding Round Completed, Bringing Total To $147 MillionSudo Biosciences completed a second close of its Series B funding in January 2024, raising $30 million from new investors, bringing the round to $147 million. The company has raised $188 million since 2020 and will use the funds to advance two TYK2 candidates into the clinic this year.FinSMEsSudo Biosciences Raises Additional $30M in Series B; Brought Total Round to $147MSudo Biosciences has raised an additional $30 million in Series B funding, bringing the total round to $147 million and its cumulative fundraising since 2020 to $188 million. The investment was led by Enavate Sciences and TPG, with participation from investors including Sanofi Ventures and Leaps by Bayer. Sudo intends to use the capital to advance two precision TYK2 inhibitors into clinical trials for conditions such as multiple sclerosis and psoriasis.Venture Capital Access OnlineSudo Biosciences Announces Second Close of Upsized Series B Financing Bringing Total Raised in Round to $147MSudo Biosciences completed the second close of its upsized Series B financing, raising an additional $30 million to bring the total round value to $147 million. New investors including Dementia Discovery Fund, Leaps by Bayer, and UPMC Enterprises joined existing backers such as Enavate Sciences and TPG in this investment. The funds will be used to advance two precision TYK2 inhibitors into clinical trials for conditions like multiple sclerosis, psoriasis, Alzheimer’s, and ALS in 2024.BioSpaceSudo Biosciences Announces Second Close of Upsized Series B Financing Bringing Total Raised in Round to $147MSudo Biosciences completed a second close of its upsized Series B financing, raising an additional $30 million to bring the total round size to $147 million. New investors including Dementia Discovery Fund, Leaps by Bayer, and UPMC Enterprises joined existing backers such as Enavate Sciences and TPG to support the development of precision TYK2 inhibitors for autoimmune and neurologic conditions. The proceeds will be used to advance two investigational candidates into clinical trials in 2024.SecSEC FORM DThe Securities and Exchange Commission has received a Form D filing from Sudo Biosciences, Inc., a Delaware corporation, indicating an exempt offering of securities. The total offering amount is $141,013,255, with $53,346,588 already sold and remaining offerings expected to be completed before a stipulated end date.